Myran DT

Bruyère Health Research Institute, Ottawa, ON, Canada. dmyran@ohri.ca.

7 papers · ORCID

ArticlePsilocybin

Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution.

Matsukubo J, Friesen EL, MacDonald-Spracklin R +5

Europe PMC2026
ArticlePsychedelics

Changes over time in hallucinogen-related emergency department visits in Ontario, Canada.

Myran DT, MacDonald-Spracklin R, Levesque AR +7

Europe PMC2026
ArticlePsychedelics

Hospital-based care for hallucinogens and risk of mania and bipolar disorder: A population-based cohort study.

Myran DT, MacDonald-Spracklin R, Pugliese M +4

Europe PMC2025
ArticleMDMA

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

Højlund M, Kafali HY, Kırmızı B +33

Europe PMC2025
ArticlePsilocybin

Psilocybin Dispensaries and Online Health Claims in Canada.

Matsukubo J, Dickson S, Xiao J +5

Europe PMC2025
ArticlePsychedelics

Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.

Myran DT, Xiao J, Fabiano N +8

Europe PMC2025
ArticlePsychedelics

Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder.

Myran DT, Pugliese M, Xiao J +9

Europe PMC2025